Pharvaris HAE Data in The Lancet: Deucrictibant Cuts Relief to 1.28 Hours

Pharvaris (Nasdaq: PHVS) announced on 8 October 2026 that full results of the RAPIDe-3 phase 3 trial of oral deucrictibant immediate-release capsules, 20 mg, for on-demand treatment of hereditary angioedema attacks were published in The Lancet, which the company cited as carrying a Journal Impact Factor of 109.0. The company said the trial met its primary endpoint and all 11 secondary endpoints, with onset of symptom relief at 1.28 hours and complete symptom resolution at 11.95 hours, both faster than placebo.

Context — why publication in The Lancet matters now

Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company said deucrictibant, if approved, would be the first approved oral bradykinin B2 receptor antagonist.

The report gives its own precedent: results from the earlier RAPIDe-1 study were published in April 2026 in The Lancet Haematology, and the company said the RAPIDe-3 results are consistent with those findings. That matters because a phase 3 readout that tracks an earlier trial is the pattern regulators weigh when reviewing an application.

The publication lands while two regulatory reviews are already open. A New Drug Application for deucrictibant IR for on-demand treatment of HAE attacks is under review with the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act target action date of 23 April 2027. A Marketing Authorization Application is under review with the European Medicines Agency.

That sequence is the catalyst chain. Publication in a high-visibility journal gives clinicians and researchers access to the full dataset before any approval decision, rather than after. The company framed the publication in exactly those terms through its lead investigator.

The backdrop for small-cap biotech is a rate environment the report does not quantify, and the company gave no financing detail. Pharvaris did not disclose the terms of any capital arrangement in this report.

Data — what the RAPIDe-3 numbers show

RAPIDe-3 was a global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant IR capsule at 20 mg for on-demand treatment of HAE attacks in adolescents and adults. It is registered as NCT06343779.

The two headline figures are time to onset of symptom relief at 1.28 hours and time to complete symptom resolution at 11.95 hours, both measured against placebo. The company also reported that deucrictibant IR achieved End of Progression of attack symptoms, symptom relief, and complete symptom resolution significantly faster than placebo.

Measure	Deucrictibant IR 20 mg	Placebo
Time to symptom relief	1.28 hours	Faster than placebo
Complete symptom resolution	11.95 hours	Faster than placebo
Endpoints met	Primary plus all 11 secondary	—

The company said most attacks were adequately controlled with a single capsule. Deucrictibant IR was reported as well tolerated with no safety signals observed. The report did not publish the placebo-arm times as separate figures, so the magnitude of the difference cannot be stated from this report alone.

Results held across subgroups defined by age, geographic location, HAE type including HAE with normal C1 inhibitor, use of long-term prophylaxis, and attack severity and location, including non-severe laryngeal attacks.

Analysis — what it means for markets and sectors

Pharvaris trades on Nasdaq under PHVS, and the equity story rests on a single asset class: oral bradykinin B2 receptor antagonism. The company is developing two formulations, an extended-release tablet for prophylactic use and an immediate-release capsule for on-demand use. The RAPIDe-3 data address only the on-demand capsule, so the prophylactic program remains a separate, unvalidated leg of the thesis.

Second-order exposure sits with the injectable on-demand HAE market. The company described bradykinin B2 receptor antagonism as a validated mechanism already widely used for on-demand treatment of HAE attacks, which means deucrictibant would compete on route of administration rather than on a novel target. The report gives no competitor names, no market size, and no pricing, so the scale of any share shift cannot be quantified from this disclosure.

The clearest limitation is that efficacy and tolerability data are not an approval. The FDA review is live with a target action date of 23 April 2027, and the EMA review has no stated date in the report. A crossover design also means every participant served as their own control, which the report does not discuss as a methodological trade-off.

Positioning is event-driven. The stock's near-term flow is tied to regulatory news rather than to the publication itself, because the top-line readout was already public before the manuscript appeared.

Outlook — what to watch next

Three items carry the story from here. The FDA's PDUFA target action date of 23 April 2027 is the single dated catalyst in the report. The EMA review of the Marketing Authorization Application is the second, with no date disclosed. The third is the ongoing open-label extension, RAPIDe-2, registered as NCT05396105, which the company said is continuing.

The report also names an expanded access program for deucrictibant IR for on-demand treatment of HAE attacks, registered as NCT07759141, available in the U.S. to people meeting eligibility requirements. Separately, the company references a CREAATE study among its ongoing and future trials in its forward-looking language, without giving timing or design.

The report names no price levels, no moving averages, and no valuation metrics for PHVS. With no stated technical reference points, the dated regulatory calendar is the only schedule a reader can work from.

Frequently Asked Questions

What does the RAPIDe-3 publication mean for retail investors in Pharvaris?

The publication itself does not change the regulatory calendar. The FDA review of the deucrictibant IR New Drug Application continues with a target action date of 23 April 2027, and the EMA review continues without a disclosed date. For shareholders, the practical effect is wider clinician and researcher visibility for the dataset ahead of those decisions, not a change in the approval timeline.

What happens next for deucrictibant IR?

The company said the New Drug Application is under review at the FDA and the Marketing Authorization Application is under review at the EMA. The open-label extension RAPIDe-2 is ongoing, and an expanded access program is available in the U.S. to eligible people. Pharvaris also stated it is investigating deucrictibant in both on-demand and prophylactic settings, with the extended-release tablet covering prophylaxis.

Why did Pharvaris say deucrictibant could be a first?

The company said deucrictibant IR would be the first approved oral bradykinin B2 receptor antagonist if regulators clear it. That claim rests on route of administration, not on the drug target, since the company describes bradykinin B2 receptor antagonism as a mechanism already widely used for on-demand HAE treatment. The report does not name the injectable products it would compete against.

Bottom Line

Pharvaris now has peer-reviewed phase 3 data in The Lancet, but the 23 April 2027 FDA decision still gates the entire commercial case.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.